Editor: Mark Shirtliff
Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus : comparison with other drugs
Article first published online: 19 MAY 2010
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved
FEMS Immunology & Medical Microbiology
Special Issue: Biofilms
Volume 59, Issue 3, pages 466–469, August 2010
How to Cite
Cafiso, V., Bertuccio, T., Spina, D., Purrello, S. and Stefani, S. (2010), Tigecycline inhibition of a mature biofilm in clinical isolates of Staphylococcus aureus : comparison with other drugs. FEMS Immunology & Medical Microbiology, 59: 466–469. doi: 10.1111/j.1574-695X.2010.00701.x
- Issue published online: 13 JUL 2010
- Article first published online: 19 MAY 2010
- Received 29 December 2009; revised 19 April 2010; accepted 12 May 2010.Final version published online 7 June 2010.
- in vitro antibiofilm tests;
- Staphylococcus aureus ;
The purpose of our study was to evaluate the anti-staphylococcal biofilm activity of tigecycline, compared with a group of recently developed or commonly used antimicrobials such as linezolid, daptomycin, levofloxacin, tobramycin and rifampin, all possessing putative antibiofilm properties, on a sample of multi-drug-resistant methicillin-resistant Staphylococcus aureus grown as a planktonic and mature biofilm. We determined conventional minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) for the planktonic forms, MICs of adherent cells and finally, minimum biofilm eradication concentrations (MBECs). No drug was able to inhibit adherent bacteria at the same concentration necessary for eradicating a mature biofilm; the latter concentrations varied from three to seven times higher than the ones inhibiting adhesion. The concentrations eradicating biofilm were reached by rifampin and daptomycin at lower concentrations with respect to the other antibiotics tested; tigecycline was able to inhibit mature biofilms at higher concentrations, while all the other antibiotics were only able to inhibit adhering cells.
Biofilms are known for their complexity (Costerton et al., 1999) and ability to resist just about everything in our current antimicrobial armory. Inside these well-organized and highly regulated structures, bacterial cells acquire different properties with respect to free-floating bacteria – among which metabolic and phenotypic specializations are acquired – diverse morphologies and a heterogeneous physiology. All these features may be responsible for the coexistence of aerobically growing, fermenting, dormant and dead cells.
It is well known that biofilms play a role in the pathogenesis of Staphylococcus aureus infections, causing many difficulties in the eradication of biofilm-associated infections (BAIs) and leading to a persistent and chronic state of many S. aureus diseases (Ceri et al., 1999; Donlan & Costerton, 2002; Hall-Stoodley et al., 2004).
Mechanisms of biofilm resistance, still not totally clear, are usually multifactorial and vary from one organism to another. It has been suggested that these resistance mechanisms can be attributed to many factors: a delayed penetration of antimicrobials through the biofilm matrix; the presence of slow or nongrowing cells within the biofilm; the heterogeneity of the biofilm bacterial population in terms of the presence of subpopulations with different phenotypic levels of resistance; and the presence of persisters (Mah & O'Toole, 2001; Harrison et al., 2005).In Pseudomonas aeruginosa, for example, the involvement of a cluster of genes, namely the ndvB locus, has been correlated with high-level biofilm-specific resistance (Mah et al., 2003). Furthermore, antimicrobial biofilm resistance can be considered as a sort of ‘population resistance’ in which the sequestration of drugs can expose bacteria to antimicrobial concentrations below therapeutic doses, within infection sites, and also below the mutant prevention concentration (Dong et al., 1999; Zhao & Drlica, 2001).
The activity of antimicrobials on biofilms depends on their molecular size, positive charges, permeability coefficient and bactericidal activity, and from this point of view, it is mandatory to test the antibiofilm activity of new drugs, potentially useful in BAIs.
Current standard assays and parameters such as minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs), performed normally on suspended cultures, are inadequate to evaluate the antimicrobial activity of slow nongrowing sessile cells, and the use of several variables (MBEC, MBIC, MIBADH, MBCADH) and methods (Calgary device method, MBIC determination, quantification of viable cells by XTT assay) complicates the interpretation of in vitro results and the understanding of antimicrobial antibacterial activity (Ceri et al., 1999; Labthavikul et al., 2003; Sandoe et al., 2006; Smith et al., 2009).
The purpose of our study was to evaluate the anti-staphylococcal biofilm activity of tigecycline, compared with a group of recently developed or commonly used antimicrobials such as linezolid, daptomycin, levofloxacin, tobramycin and rifampin, all possessing putative antibiofilm properties, on a sample of multi-drug-resistant methicillin-resistant S. aureus (MRSA) grown as a planktonic and mature biofilm. We determined conventional MICs and MBCs for the planktonic forms, MICS of adherent cells and finally, minimum biofilm eradication concentrations (MBECs).
Materials and methods
Our sample included 30 previously identified biofilm-producing MRSA strains collected in our laboratory from central venous catheters or sputum of cystic fibrosis patients. Isolates were grown on mannitol–salt–agar (MSA) plates (Oxoid, Basingstoke, UK) identified by the coagulase test and the Api-Staph System (Bio-Merieux), and maintained at −80 °C until use.
The biofilm-forming ability of S. aureus was tested in a static system using a spectrophotometrical quantitative assay. Each strain was grown in tryptone soy broth (Oxoid), with the addition of 0.25% glucose (TSBG). These assays were performed in microtitre plates as described previously (Christensen et al., 1985; Ziebuhr et al., 1999; Cafiso et al., 2007). Each reported value is the average of 12 measurements at 490 nm.
MICs and MBCs
Conventional MICs and MBCs of tigecycline, levofloxacin, linezolid, daptomycin, tobramycin and rifampin were determined in duplicate using Clinical and Laboratory Standard Institute (CLSI) (2009) guidelines.
Biofilm susceptibility tests
Each MICadh and MBEC experiment, conducted in parallel with MIC and MBC, was carried out in the presence of tigecycline, levofloxacin, linezolid, daptomycin, tobramycin and rifampin.
The MICadh was the lowest antimicrobial concentration at which there was no observable bacterial growth in the wells containing adherent microcolonies. Briefly, the MICadh test was performed and evaluated as published previously (Labthavikul et al., 2003), with the following modifications: the bacterial suspensions used were at a density of 108 CFU mL−1; this suspension was prepared in phosphate-buffered saline (PBS) and diluted 1 : 30 in TSBG.
The MBEC, read as the lowest antimicrobial concentration at which bacteria fail to regrow after exposure to the antibiotic, was performed using a modified version of the Calgary biofilm device method (Ceri et al., 1999).
Isolates grown overnight in TSBG were adjusted to a turbidity of 1.0 McFarland standard, validated by viable counts on tryptone soy agar plates and diluted 1 : 30 in fresh TSBG. An 200-μl aliquot was then placed in each row of a 96-well flat-bottom microtitre plate (Nuclon Delta, Nunc, Denmark), covered with a 96-peg lid (Nunc-TSP; Nunc) and statically incubated overnight for biofilm formation on the pegs.
To remove planktonic cells, the peg lid was rinsed three times in 1 × sterile PBS, placed on a new plate filled with 200 μL of fresh broth containing serial dilutions of antibiotics as described by CLSI guidelines and incubated overnight at 37 °C. The peg lid was then placed onto a plate containing a fresh medium and the sessile cells were removed by bath sonication for 5 min at 40 kHZ (Bransonic 2510, Branson Ultrasonics Corporation, Danbury). Finally, the peg lid was discarded and replaced with a new lid. The plates were incubated for 24 h at 37 °C, and after this incubation, the MBEC was recorded. All assays were conducted in triplicate.
The MICs and MBCs of the planktonic cells, and biofilm inhibition and eradication as determined by MICadh and MBEC measurements, respectively, are summarized in Table 1. The results obtained on planktonic forms showed that all antibiotics tested were variably bactericidal, with MBCs90 ranging from one dilution higher than the MIC90 value to ≥3 dilutions higher for bacteriostatic agents.
|Antimicrobial agent||Planktonic bacteria (mg L−1)||Adherent bacteria (mg L−1)|
|MIC range||MIC50||MIC90||MBC range||MBC50||MBC90||MICadh range||MIC50adh||MIC90adh||MBEC range||MBEC50||MBEC90|
The results on biofilm cells showed that MIC50adh of tigecycline, linezolid, daptomycin and rifampin were 0.5, 4 and 1 mg L−1, respectively, similar to the inhibition values obtained in planktonic growth and remaining within the susceptibility breakpoints. Only the MIC50adh of levofloxacin (8 mg L−1) and tobramycin (128 mg L−1) were resistant values for the two antibiotics.
MIC90adh of tigecycline and rifampin had the same values as their MIC50adh (0.5 and 1 mg L−1), whereas a value of one dilution higher than MIC50adh was registered in the MIC90adh both for daptomycin (2 mg L−1) and for levofloxacin (16 mg L−1). A MIC90adh value more than one dilution higher than MIC50adh was found for linezolid and tobramycin, which showed 64 and >128 mg L−1 MIC90adh, respectively.
The MIC90adh of tigecycline (0.5 mg L−1) and rifampin (1 mg L−1) remained within the susceptibility breakpoints.
Comparing MIC90adh with MIC90, it is necessary to emphasize that tigecycline and rifampin MIC90adh presented only a one- to twofold increase with respect to their MIC90, whereas for linezolid, daptomycin and tobramycin, a two- to fourfold increase was found. The levofloxacin MIC90 and MIC90adh were 16 mg L−1.
MBEC50 and MBEC90 of rifampin and daptomycin were 16 mg L−1, whereas for tigecycline, the MBEC90 was 64 mg L−1 and the MBEC50 was 16 mg L−1.
Moreover, evaluating MBEC90 and MBC90, it was found that the MBEC90 values were at least three dilutions higher than the MBC90 values for all tested antimicrobials, with values of 64 and 2 mg L−1 for tigecycline, 16 and 1 mg L−1 for daptomycin, 16 and 2 mg L−1 for rifampin, >128 and >16 mg L−1 for linezolid, >128 and 32 mg L−1 for levofloxacin and >128 and 128 mg L−1 for tobramycin.
Biofilm formation, as described in numerous papers, represents a major obstacle for the clinical efficacy of antimicrobial agents. The results of conventional antimicrobial susceptibility testing are difficult to apply to bacteria in biofilms because traditional antimicrobial treatments fail to eradicate surface-attached bacteria (Patel, 2005). It seems logical that biofilm-eradicating concentrations of drugs are necessary for a positive therapeutic outcome in BAIs such as endocarditis, and foreign body and prosthetic infection (Ceri et al., 1999; Zimmerli & Ochsner, 2003). Different research groups have investigated the activity of new anti-Gram-positive drugs such as tigecycline, alone or in combination with linezolid and daptomycin against biofilm-producing staphylococci, but not all studies are comparable in terms of methodologies and, ultimately, in terms of the concordance of the results obtained (Petersen et al., 2002; Labthavikul et al., 2003; Raad et al., 2007; Hajdu et al., 2009; Presterl et al., 2009; Rose & Poppens, 2009; Smith et al., 2009).
In the present study, all antibiotics tested acted diversely in inhibiting or eradicating structured and mature biofilms. No drug was able to inhibit adherent bacteria at the same concentration necessary for eradicating mature biofilm; the latter concentrations varied from three to seven times higher than those inhibiting adhesion. The concentrations eradicating biofilm were reached by rifampin and daptomycin at lower concentrations compared with the other antibiotics tested; tigecycline inhibited mature biofilms at higher concentrations, while all the other antibiotics were only able to inhibit adhered cells.
In conclusion, we used different in vitro susceptibility testing methods to examine how antimicrobial agents affect mature biofilms produced by clinical isolates of S. aureus. Our results suggest that tigecycline, daptomycin and rifampin are promising as useful agents for eradicating S. aureus biofilm infections, while the other drugs tested were only able to inhibit adherent cells. The concentrations required for biofilm eradication are three to five times higher than the concentrations required for inhibiting adherent cells. These effects may be an important factor in the selection of antimicrobial therapy for this virulent organism.
- 2007) agr-Genotyping and transcriptional analysis of biofilm-producing Staphylococcus aureus. FEMS Immunol Med Mic 51: 220–227. , , , , , & (
- 1999) The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37: 1771–1776. , , , , & (
- 1985) Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22: 996–1006. , , , , , & (
- Clinical and Laboratory Standard Institute (CLSI) (2009) Performance Standard for Antimicrobial Susceptibility Testing. CLSI M100 and S19 Vol. 29 n. 3. CLSI, Wayne, PA.
- 1999) Bacterial biofilms: a common cause of persistent infections. Science 21: 1318–1322. , & (
- 1999) Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Ch 43: 1756–1758. , , & (
- 2002) Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167–193. & (
- 2009) Effects of vancomycin, daptomycin, fosfomycin, tigecycline and ceftriaxone on Staphylococcus epidermidis biofilms. J Orthop Res 27: 1361–1365. , , , & (
- 2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2: 95–108. , & (
- 2005) Biofilms: a new understanding of these microbial communities is driving a revolution that may transform the science of microbiology. Am Sci 93: 508–551. , , & (
- 2003) In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Ch 47: 3967–3969. , & (
- 2001) Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 9: 34–39. & (
- 2003) A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426: 306–310. , , , , & (
- 2005) Biofilms and antimicrobial resistance. Clin Orthop Relat R 437: 41–47. (
- 2002) In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Ch 46: 2595–2601. , , , , & (
- 2009) Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms. Antimicrob Agents Ch 53: 3205–3210. , , , , & (
- 2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Ch 51: 1656–1660. , , , , , , & (
- 2009) Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemoth 63: 485–488. & (
- 2006) Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemoth 57: 767–770. , , , & (
- 2009) Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Ag 33: 374–378. , , , & (
- 2001) Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 33: S147–S156. & (
- 1999) A novel mechanism of phase variation of virulence in Staphylococcus epidermidis: evidence for control of polysaccharide intercellular adhesin synthesis by alterning insertion and excision of the insertion sequence element IS256. Mol Microbiol 32: 345–356. , , , , & (
- 2003) Management of infection associated with prosthetic joints. Infection 31: 99–108. & (